A global pharmaceutical company evaluated vertical integration across the LNP lipid supply chain during the COVID-driven demand surge. The question: acquire, build (CAPEX), or rely on suppliers.
- Framed the decision as a capital allocation problem
- Stress-tested demand at peak pandemic levels and modeled post-cycle normalization
- Evaluated integration value under realistic utilization scenarios
- Determined that peak demand did not support acquisitions
- Anticipated normalization and reduced input demand
- Recommended relying on suppliers to absorb capacity risk
- Preserved capital and strategic flexibility
Subsequent market developments confirmed this view, with suppliers bearing the impact of demand normalization.
Capital allocation advisory • Strategic diligence • Market analysis • Scenario modeling
A high-growth US platform company was raising a $125MM Series C, supported by aggressive market projections and proprietary technology claims.
- Conducted independent technical, commercial, and market diligence
- Assessed IP robustness and scalability constraints
- Refined market sizing and adoption assumptions
- Audited cost structures and scale-up economics
- Rebased revenue expectations to a credible range
- Identified material IP and supply chain risks
- Strengthened the investor’s position in valuation discussions
- Refocused the investment case on achievable growth
Strategic diligence • Technical assessment • Market analysis • Financial validation • Investment support